Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations
Status:
SUSPENDED
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
This is an open label, phase II trial in subjects with treatment naïve, metastatic hormone sensitive prostate cancer (mHSPC) with deleterious homologous recombination repair (HRR) alteration(s). These include pathologic alterations in BRCA 1/2, BRIP1, CHEK2, FANCA, PALB2, RAD51B, and/or RAD54L. A total of 64 people will be enrolled to the study.
Phase:
PHASE2
Details
Lead Sponsor:
Qian Qin
Collaborators:
Janssen, LP UT Southwestern Comprehensive Cancer Center